Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Leukemia·2026
Same author

European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.

Blood cancer journal·2025
Same author

SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia-How to Define the Treatment Value?

Clinical lymphoma, myeloma & leukemia·2025
Same author

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.

Leukemia·2025
Same author

Management of chronic myeloid leukemia in 2025.

Cancer·2025
Same author

Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY.

Leukemia & lymphoma·2025

Related Experiment Video

Updated: May 21, 2026

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

How I treat CML blast crisis.

Rüdiger Hehlmann1

  • 1III Medizinische Klinik, Medizinische Fakultät Mannheim, Ruprecht-Karls-Universität, Heidelberg, Germany.

Blood
|June 2, 2012
PubMed
Summary

Blast crisis (BC) in chronic myeloid leukemia (CML) is driven by BCR-ABL activity, causing genetic instability. Allogeneic stem cell transplantation offers the best cure chance, while early BCR-ABL elimination is key for prevention.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Blast crisis (BC) is the most challenging phase of chronic myeloid leukemia (CML).
  • Continued BCR-ABL activity drives BC through genetic instability, DNA damage, and impaired DNA repair.
  • BC often involves multiple mutations and chromosomal aberrations.

Purpose of the Study:

  • To review the current understanding and management of CML in blast crisis.
  • To highlight the role of tyrosine kinase inhibitors (TKIs) and allogeneic stem cell transplantation (SCT).
  • To emphasize the importance of early BCR-ABL elimination for BC prevention.

Main Methods:

  • Review of existing literature on CML blast crisis.
  • Analysis of treatment outcomes with TKIs and SCT.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Experiment Videos

Last Updated: May 21, 2026

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

  • Discussion of genetic factors and mutation profiles in BC.

    • Main Results:

    • TKIs offer modest survival improvements in BC, but SCT remains the most effective curative option.
    • Most long-term survivors achieve cure through allogeneic SCT.
    • Investigational agents are unlikely to offer significant alternatives soon.

    Conclusions:

    • Allogeneic SCT provides the best chance for cure in CML blast crisis.
    • Treatment strategies should focus on achieving a second chronic phase and proceeding to SCT.
    • Preventing BC through early and rigorous BCR-ABL elimination is crucial.